Clinical trials: Brain Structure
Ischemic Stroke
Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment…
- Trial name
- RODIN (NCT05041010)
- Testing
- Neu2000KWL group
- Where
- 24 sites in South Korea
- Volunteers
- 496 people
- Sponsor
- GNT Pharma
Alzheimer Disease
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild…
- Trial name
- NCT00153010
- Testing
- NS 2330 (Tesofensine)
- Where
- 87 sites in United States, Canada
- Volunteers
- 430 people
- Sponsor
- Boehringer Ingelheim
Stroke, Ischemic, Stroke Hemorrhagic
Evaluation of the Effectiveness and Safety of Keeogo™ Dermoskeleton in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the Keeogo™ Dermoskeleton in subjects with hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Hemiparesis
- Trial name
- NCT03986320
- Testing
- Keeogo™ Dermoskeleton
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- B-Temia, Inc.
Epilepsy
Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
The primary efficacy parameter will be the responder rate, defined as the proportion of subjects who had at least a 50% reduction in 28 day seizure rate during the maintenance phase
- Trial name
- NCT00684424
- Testing
- Non-Interventional Study
- Volunteers
- 199 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Growth Hormone Deficiency With Pituitary Anomalies
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial.
- Trial name
- NCT02558829
- Testing
- Macimorelin, Insulin
- Where
- 27 sites in United States, Austria and 7 more
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- AEterna Zentaris
Growth Hormone Deficiency
A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency
This study is a multi-center, open-label safety study assessing long-term somavaratan administration.
- Trial name
- NCT03145831
- Testing
- Somavaratan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Versartis Inc.
Parkinsons Disease (PD), Healthy Elderly Volunteers
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
This is a single-center, open-label clinical study designed to evaluate alpha-synuclein (ASYN) deposition in the brain of participants with Parkinson's disease (PD), as compared with healthy elderly (HE) participants.
- Trial name
- NCT07880379
- Testing
- [¹⁸F]MK-0947
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XingImaging, LLC
Phenylketonuria (PKU) and Hyperphenylalaninemia, Brain Diseases, Metabolic, Inborn
Market Research of a Slow Release Protein Substitute for the Dietary Management of PKU
XPhePiccosMR is a prospective, single-arm, open label, observational study that aims to evaluate the acceptability and tolerability of XPhe Piccos, a slow-release, phenylalanine-free protein substitute in the form of tiny…
- Conditions
- Phenylketonuria (PKU) and Hyperphenylalaninemia, Brain Diseases, Metabolic, Inborn, Brain Disorder, Metabolic, Brain Diseases
- Trial name
- XPhePiccosMR (NCT07802366)
- Testing
- Slow release, phenylalanine-free protein substitute tablets
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- metaX Institut fuer Diatetik GmbH
Dyskinesia, Levodopa-Induced Dyskinesia (LID)
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- EASE LID 3 (NCT02274766)
- Testing
- ADS-5102
- Where
- 51 sites in United States, Austria and 3 more
- Volunteers
- 77 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Acute Repetitive Seizures, Breakthrough Seizures
Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects
This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1
- Trial name
- NCT02721069
- Testing
- NRL-1
- Where
- 5 sites in United States
- Volunteers
- 175 people
- Sponsor
- Neurelis, Inc.
Insomnia, TBI (Traumatic Brain Injury)
Behavioral Treatment of Insomnia in Active-Duty Service Members With Traumatic Brain Injury
The objective of the study is to conduct a randomized controlled trial of Cognitive Behavioral Therapy for Insomnia (CBT-I) in a sample of active-duty sailors with a history of traumatic brain injury (TBI).
- Trial name
- CBTBI (NCT06867666)
- Testing
- In Person CBT-I, CBT-I via COAST
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Noctem, LLC
Brain Diseases, Cardiovascular Diseases
pRESET for Occlusive Stroke Treatment
Compare the safety and effectiveness of pRESET to Solitaire in the treatment of stroke related to large vessel occlusion
- Conditions
- Brain Diseases, Cardiovascular Diseases, Central Nervous System Diseases, Cerebrovascular Disorders
- Trial name
- PROST (NCT03994822)
- Testing
- Mechanical Thrombectomy using the pRESET Thrombectomy device, Mechanical Thrombectomy using the Solitaire Revascularization Device
- Where
- 24 sites in United States, Germany
- Volunteers
- 340 people
- Sponsor
- phenox Inc.
Japanese Encephalitis
Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.
- Trial name
- NCT00596102
- Testing
- Japanese Encephalitis purified inactivated vaccine
- Volunteers
- 3,258 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Parkinson Disease
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind…
- Trial name
- NCT00601523
- Testing
- Pramipexole
- Where
- 119 sites in United States, Austria and 13 more
- Volunteers
- 511 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered…
- Trial name
- LoCaMoTE-PD (NCT07005180)
- Testing
- HBI-002
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Hillhurst Biopharmaceuticals, Inc.
Multiple System Atrophy
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
- Trial name
- NCT06848231
- Testing
- YA-101
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 75 people
- Sponsor
- Dasher Neuroscience Inc.
Parkinson Disease
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics
The purpose of the study was to To investigate whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose…
- Trial name
- NCT03094156
- Testing
- BIA 6-512, Madopar® 250, Comtan®
- Where
- Portugal
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer Disease, Vascular Dementia
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
The purpose of this study is to evaluate the safety and efficacy of galantamine (a drug for treating dementia) compared to placebo in the treatment of patients with dementia related to cerebrovascular disease (vascular dementia)…
- Trial name
- NCT00261573
- Testing
- galantamine hydrobromide
- Volunteers
- 593 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Parkinson Disease
Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects
the purpose of the study was to the compare pharmacokinetic profile of BIA 6-512 in healthy elderly subjects versus healthy young subjects after single and repeated oral administration of 200 mg BIA 6-512.
- Trial name
- NCT03095105
- Testing
- 200 mg BIA 6-512
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer's Type Dementia
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.
- Trial name
- NCT01539031
- Testing
- E2020
- Where
- 54 sites in Japan
- Volunteers
- 351 people
- Sponsor
- Eisai Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.